TriangleNCT01730586 · OUTCOME
Progression-Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Assessed at first cycle (21 days), up to 12 months
What was measured
The length of time during and after the treatment a participant lives without disease progression. Time to progression functions estimated using the Kaplan-Meier method. Participants who drop out of the study included in the time to event data analysis as "censored data".
Analysis population: For progression-free survival, the intent-to-treat analysis performed using all available participants.
Groups in this outcome
CIMP-high Colorectal Cancer
Abraxane 220 mg/m\^2 intravenously on Day 1 of 21 day cycle.
Small Bowel Adenocarcinoma
Abraxane 220 mg/m\^2 intravenously on Day 1 of 21 day cycle.
| Group | Source count |
|---|---|
| CIMP-high Colorectal Cancer | 21 |
| Small Bowel Adenocarcinoma | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CIMP-high Colorectal Cancer | 2.1 | Not reported | 1.7 | 2.5 | Not reported |
| Small Bowel Adenocarcinoma | 3.2 | Not reported | 2.6 | 3.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.7
- upper Limit
- 2.5
- value
- 2.1
- group Id
- OG001
- lower Limit
- 2.6
- upper Limit
- 3.8
- value
- 3.2
- denoms
- counts
- group Id
- OG000
- value
- 21
- group Id
- OG001
- value
- 13
- units
- Participants
- description
- The length of time during and after the treatment a participant lives without disease progression. Time to progression functions estimated using the Kaplan-Meier method. Participants who drop out of the study included in the time to event data analysis as "censored data".
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Abraxane 220 mg/m\^2 intravenously on Day 1 of 21 day cycle.
- id
- OG000
- title
- CIMP-high Colorectal Cancer
- description
- Abraxane 220 mg/m\^2 intravenously on Day 1 of 21 day cycle.
- id
- OG001
- title
- Small Bowel Adenocarcinoma
- param Type
- MEDIAN
- population Description
- For progression-free survival, the intent-to-treat analysis performed using all available participants.
- reporting Status
- POSTED
- time Frame
- Assessed at first cycle (21 days), up to 12 months
- title
- Progression-Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice